Brooklyn ImmunoTherapeutics Profit Margin

The latest profit margin for BTX is -7513.88% as of September 2024. That compares with -39223.53% in the prior-year period — up 80.8% year over year. That is below the Telecommunications sector average of 13.41%. Investors often review this figure alongside Brooklyn ImmunoTherapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, BTX's profit margin moved from -39223.53% to -7513.88% — a 80.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Brooklyn ImmunoTherapeutics's valuation or profitability profile.

Against Telecommunications companies, BTX currently prints -7513.88% for profit margin, while the sector average sits near 13.41%. That is roughly 56148.5% below the sector mean. Large gaps often invite a closer look at Brooklyn ImmunoTherapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Brooklyn ImmunoTherapeutics converts resources into returns. At -7513.88%, BTX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -39223.53% in the prior-year period — up 80.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting BTX's profit margin (-7513.88%), review year-over-year change from -39223.53%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.